Jonathan D Roth

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. ncbi Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, San Diego, California, USA
    Curr Opin Endocrinol Diabetes Obes 20:8-13. 2013
  2. ncbi GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc San Diego, CA, USA
    Br J Pharmacol 166:121-36. 2012
  3. ncbi Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents
    J D Roth
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Diabetes Obes Metab 14:608-15. 2012
  4. ncbi Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Dr, San Diego, CA 92121, USA
    Am J Physiol Endocrinol Metab 293:E1112-7. 2007
  5. ncbi "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Brain Res 1350:86-94. 2010
  6. ncbi Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Arch Neurol 66:306-10. 2009
  7. ncbi Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 147:5855-64. 2006
  8. ncbi Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
    J D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Int J Obes (Lond) 32:1201-10. 2008
  9. ncbi Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 105:7257-62. 2008
  10. ncbi Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Endocrinology 148:6054-61. 2007

Collaborators

Detail Information

Publications22

  1. ncbi Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, San Diego, California, USA
    Curr Opin Endocrinol Diabetes Obes 20:8-13. 2013
    ..This review focuses on recent advances in receptor signaling, neurobiology, and pharmacological interactions of amylin with nutritive status, as well as other metabolism-related regulatory signals...
  2. ncbi GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc San Diego, CA, USA
    Br J Pharmacol 166:121-36. 2012
    ..Finally, the future of GLP-1- and amylin agonist-based therapeutics is discussed...
  3. ncbi Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents
    J D Roth
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Diabetes Obes Metab 14:608-15. 2012
    ..Amylinergic and melanocortinergic systems have each been implicated in energy balance regulation. We examined the interactive effects of both systems using gene knockout and pharmacological approaches...
  4. ncbi Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Dr, San Diego, CA 92121, USA
    Am J Physiol Endocrinol Metab 293:E1112-7. 2007
    ..These results indicate that amylin's anorexigenic and fat-specific weight loss properties can be extended to a variety of nutritive states in female rats...
  5. ncbi "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Brain Res 1350:86-94. 2010
    ..Finally, we briefly discuss what the future landscape of neurohormonal anti-obesity combinations may hold...
  6. ncbi Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Arch Neurol 66:306-10. 2009
    ..Herein, we link amylin activation of central neural circuits to these therapeutic effects, and we speculate on other potential therapeutic applications of amylin receptor agonism...
  7. ncbi Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 147:5855-64. 2006
    ..05 vs. VEH). In a rodent model of obesity, amylin reduced body weight and body fat, with relative preservation of lean tissue, through anorexigenic and specific metabolic effects...
  8. ncbi Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
    J D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Int J Obes (Lond) 32:1201-10. 2008
    ..To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats...
  9. ncbi Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 105:7257-62. 2008
    ....
  10. ncbi Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Endocrinology 148:6054-61. 2007
    ..Collectively, these observations highlight the importance of studying peptide hormones in combination and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity...
  11. ncbi Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, United States
    Physiol Behav 100:187-95. 2010
    ....
  12. ncbi Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 149:5679-87. 2008
    ..We conclude that amylin/leptin interact synergistically to reduce body weight and adiposity in diet-induced obese rodents through a number of anorexigenic and metabolic effects...
  13. ncbi Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California, USA
    Obesity (Silver Spring) 18:21-6. 2010
    ....
  14. ncbi Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Am J Physiol Gastrointest Liver Physiol 302:G762-72. 2012
    ..Our pharmacological data further support the clinical evaluation of the utility of GLP-1R agonists for treatment of NASH...
  15. ncbi Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Endocrinology 151:5657-68. 2010
    ..These findings support the clinical investigation of amylin in low estradiol (e.g. postmenopausal) states...
  16. ncbi Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy
    Hubert C Chen
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Curr Diabetes Rev 4:79-91. 2008
    ..If confirmed in ongoing translational clinical research studies, these findings may provide a physiological rationale for a novel, integrated neurohormonal approach to pharmacotherapy for obesity...
  17. ncbi Insights into amylin-leptin synergy
    James L Trevaskis
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Trends Endocrinol Metab 21:473-9. 2010
    ..Understanding how amylin agonism improves leptin function could point to general therapeutic strategies for combating leptin resistance and associated obesity...
  18. ncbi It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development
    Jean L Chan
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    J Investig Med 57:777-83. 2009
    ..Collectively, these findings suggest that combined amylin/leptin agonism may have therapeutic utility as part of an integrated, neurohormonal approach to obesity pharmacotherapy...
  19. ncbi Mechanisms of amylin/leptin synergy in rodent models
    Victoria F Turek
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, California 92121, USA
    Endocrinology 151:143-52. 2010
    ....
  20. ncbi Hormone-based therapies in the regulation of fuel metabolism and body weight
    Nicole C Kesty
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Expert Opin Biol Ther 8:1733-47. 2008
    ..Dysregulation in these neurohormonal pathways probably contributes to pathogenesis of obesity and type 2 diabetes...
  21. ncbi Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
    Jason R Clapper
    Amylin Pharmaceuticals, LLC, San Diego, CA 92121, USA
    Eur J Pharmacol 698:292-8. 2013
    ..These findings support the strategy of combined amylin agonism with opioid and catecholaminergic signaling systems for the treatment of obesity...
  22. ncbi Modeling the pathways of energy balance using the N1E-115 murine neuroblastoma cell line
    Jonathan D Roth
    Department of Animal Biology, School of Vetrinary Medicine and the Institute of Neurological Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA
    Brain Res Mol Brain Res 103:146-50. 2002
    ..N1E-115 murine neuroblastoma cells have emerged as an attractive candidate for further analysis because they contain mRNA for a variety of key systems implicated in the regulation of energy homeostasis...